|View printer-friendly version|
|July 18, 2008 3:16 p.m.|
|Teva and Barr Invites Public to Listen to Webcast|
|Jerusalem, Israel, and Montvale, New Jersey, July 18, 2008 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and Barr Pharmaceuticals, Inc. (NYSE: BRL) will host a live audio webcast of their investor meeting discussing Teva's acquisition of Barr on Monday, July 21, 2008, from 12:30-2:00 p.m. ET.|
What: Teva's Acquisition of Barr
When: Monday, July 21, 2008 from 12:30-2:00 p.m. ET
Where: www.tevapharm.com or www.barrlabs.com
How: Live over the Internet Log on to the Web at the address above and register for the event (approx. 10 minutes before). An archive of the webcast will be available on Teva's and Barr's Web sites.
Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative pharmaceuticals and active pharmaceutical ingredients. Over 80 percent of Teva's sales are in North America and Western Europe.
Barr Pharmaceuticals, Inc., headquartered in Montvale, New Jersey, is a global specialty pharmaceutical company that operates in more than 30 countries worldwide and is engaged in the development, manufacture and marketing of generic and proprietary pharmaceuticals, biopharmaceuticals and active pharmaceutical ingredients. A holding company, Barr operates through its principal subsidiaries: Barr Laboratories, Inc., Duramed Pharmaceuticals, Inc. and PLIVA d.d. and its subsidiaries. The Barr Group of companies markets more than 120 generic and 27 proprietary products in the U.S. and approximately 1,025 products globally outside of the U.S.